We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




New Method for Killing Stem Cells May Lead to Leukemia Cure

By LabMedica International staff writers
Posted on 01 Mar 2012
Print article
Blocking the activity of the histone diacetylase enzyme sirtuin 1(SIRT1) was found to increase the activity of the p53 tumor suppressor gene, which was then able to orchestrate the destruction of leukemia stem cells and eliminate the disease.

Treatment of chronic myelogenous leukemia (CML) with BCR-ABL tyrosine kinase inhibitors (TKI) prolong patient survival but fail to eliminate quiescent leukemia stem cells (LSC) that are resistant to these drugs and eventually cause the cancer to recur.

Previous studies had shown that SIRT1, a histone deacetylase involved in numerous critical cell processes including DNA repair and apoptosis that protect stem cells from stress, was overexpressed in LSCs. Therefore, investigators at the City of Hope National Medical Center (Duarte, CA, USA) examined the effect of blocking SIRT1 activity on these cells.

They reported in the February 14, 2012, issue of the journal Cancer Cell that pharmacological inhibition of SIRT1 or genetically engineered knockdown of its enzymatic activity increased apoptosis in LSC in both chronic phase and blast crisis CML and reduced their growth in vitro and in vivo. The benefits of blocking SIRT1 were enhanced by cotreatment with the BCR-ABL TKI imatinib.

SIRT1 inhibition increased p53 acetylation and transcriptional activity in CML progenitors, and the inhibitory effects of SIRT1 targeting on CML cells depended on p53 expression and acetylation.

“Tyrosine kinase inhibitors do not eliminate leukemia stem cells, which remain a potential source of cancer recurrence,” said senior author Dr. Ravi Bhatia, professor of hematology at the City of Hope National Medical Center. “CML patients need to take tyrosine kinase inhibitor treatment indefinitely, which carries a significant risk of toxicity, lack of compliance, drug resistance, relapse, and associated expense.”

The results of this study suggest that activation of p53 via SIRT1 inhibition may be a viable approach to prevent CML relapse.

Related Links:
City of Hope National Medical Center


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Antipsychotic TDM AssaysSaladax Antipsychotic Assays
New
Monkeypox Test
Monkeypox Virus Rapid Antibody Test
New
Progesterone Serum Assay
Progesterone ELISA Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: QScout CBC will give a complete blood count in 2 minutes from fingerstick or venous blood (Photo courtesy of Ad Astra Diagnostics)

Next Gen CBC and Sepsis Diagnostic System Targets Faster, Earlier, Easier Results

Every hour is critical in protecting patients from infections, yet there are currently limited tools to assist in early diagnosis before patients reach a hospital. The complete blood count (CBC) is a common... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more

Technology

view channel
Image: Schematic diagram of nanomaterial-based anti-epileptic drug concentration diagnostic technology (Photo courtesy of KRISS)

Nanomaterial-Based Diagnostic Technology Accurately Monitors Drug Therapy in Epilepsy Patients

Many patients with epilepsy take anti-epileptic drugs to control frequent seizures in their daily lives. To optimize treatment and avoid side effects from overdosing, it is crucial for patients to regularly... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.